Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676386 · ClinicalTrials.gov registry record
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
A clinical trial, sponsored by Addario Lung Cancer Medical Institute.
- Terminated
- Registry status
- 29
- Enrollment target
NCT04676386 is a clinical trial that was terminated before completion, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 29 participants.
The verdict
NCT04676386 was terminated before completion, sponsored by Addario Lung Cancer Medical Institute.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) \> 50% and ECOG performance status (PS) 0-2 NSCLC patients who are treated with PD-1/PD-L1 based therapy with or without the addition of platinum based chemotherapy.
Interventions
- DIAGNOSTIC_TEST Primary Immune Response (PIR) test by Biodesix, Inc.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676386
The ClinicalTrials.gov registry entry for NCT04676386 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addario Lung Cancer Medical Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Primary Immune Response (PIR) test by Biodesix, Inc. is the first listed.
NCT04676386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04676386 about?
NCT04676386 is a clinical study titled "Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy". This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) \> 50% and ECOG performance status (PS) 0-2 NSCLC patients who are treated with PD-1/PD-L1 ...
What is the current status of trial NCT04676386?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2021-02-01. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04676386?
The interventions under investigation include: Primary Immune Response (PIR) test by Biodesix, Inc. (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04676386?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.